Bioceres Crop Solutions Statistics
Total Valuation
BIOX has a market cap or net worth of $21.24 million. The enterprise value is $246.38 million.
Important Dates
The last earnings date was Monday, May 11, 2026, after market close.
| Earnings Date | May 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BIOX has 63.48 million shares outstanding. The number of shares has increased by 1.55% in one year.
| Current Share Class | 63.48M |
| Shares Outstanding | 63.48M |
| Shares Change (YoY) | +1.55% |
| Shares Change (QoQ) | +0.20% |
| Owned by Insiders (%) | 1.31% |
| Owned by Institutions (%) | 8.40% |
| Float | 44.25M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.08 |
| Forward PS | 0.27 |
| PB Ratio | 0.31 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.97 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.88, with a Debt / Equity ratio of 2.51.
| Current Ratio | 0.88 |
| Quick Ratio | 0.56 |
| Debt / Equity | 2.51 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -0.31 |
Financial Efficiency
Return on equity (ROE) is -32.22% and return on invested capital (ROIC) is -2.81%.
| Return on Equity (ROE) | -32.22% |
| Return on Assets (ROA) | -0.87% |
| Return on Invested Capital (ROIC) | -2.81% |
| Return on Capital Employed (ROCE) | -3.97% |
| Weighted Average Cost of Capital (WACC) | 9.55% |
| Revenue Per Employee | $339,824 |
| Profits Per Employee | -$329,233 |
| Employee Count | 751 |
| Asset Turnover | 0.38 |
| Inventory Turnover | 2.21 |
Taxes
In the past 12 months, BIOX has paid $8.33 million in taxes.
| Income Tax | 8.33M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -92.71% in the last 52 weeks. The beta is 0.39, so BIOX's price volatility has been lower than the market average.
| Beta (5Y) | 0.39 |
| 52-Week Price Change | -92.71% |
| 50-Day Moving Average | 0.46 |
| 200-Day Moving Average | 1.02 |
| Relative Strength Index (RSI) | 31.87 |
| Average Volume (20 Days) | 309,867 |
Short Selling Information
The latest short interest is 872,016, so 1.37% of the outstanding shares have been sold short.
| Short Interest | 872,016 |
| Short Previous Month | 866,373 |
| Short % of Shares Out | 1.37% |
| Short % of Float | 1.97% |
| Short Ratio (days to cover) | 2.89 |
Income Statement
In the last 12 months, BIOX had revenue of $255.21 million and -$247.25 million in losses. Loss per share was -$3.88.
| Revenue | 255.21M |
| Gross Profit | 93.42M |
| Operating Income | -9.21M |
| Pretax Income | -62.64M |
| Net Income | -247.25M |
| EBITDA | -3.90M |
| EBIT | -9.21M |
| Loss Per Share | -$3.88 |
Full Income StatementBalance Sheet
The company has $14.90 million in cash and $240.00 million in debt, giving a net cash position of -$225.10 million or -$3.55 per share.
| Cash & Cash Equivalents | 14.90M |
| Total Debt | 240.00M |
| Net Cash | -225.10M |
| Net Cash Per Share | -$3.55 |
| Equity (Book Value) | 95.60M |
| Book Value Per Share | 1.07 |
| Working Capital | -36.80M |
Full Balance SheetCash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 5.32M |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
Gross margin is 36.60%, with operating and profit margins of -3.61% and -96.88%.
| Gross Margin | 36.60% |
| Operating Margin | -3.61% |
| Pretax Margin | -24.55% |
| Profit Margin | -96.88% |
| EBITDA Margin | -1.53% |
| EBIT Margin | -3.61% |
| FCF Margin | n/a |